I'm Dr. Lauren Leavitt, founder of Billie Jean Health. This is the page I wish existed when patients ask me to compare these two medications - most of what's written on the subject is either a shrug or a sales pitch. Let me try for a straight answer, including the parts that don't flatter either drug.
The short answer
Semaglutide and tirzepatide share the same core side effect profile: nausea, diarrhea, vomiting, constipation, and abdominal discomfort, concentrated in the weeks when the dose is going up.
Where they differ is mostly a matter of degree, and the data are messier than the internet suggests. In the one large head-to-head trial, tirzepatide produced greater average weight reduction and had somewhat fewer discontinuations for gastrointestinal reasons - but that trial was not designed to compare safety, and its authors said so.
The rare-but-serious warnings are close between the two. Both carry the same boxed warning. Both are contraindicated in the same two groups of people.
Here's what matters more than the comparison: for most people, the biggest determinant of how these medications feel isn't which molecule you're on. It's how carefully the dose is escalated and how quickly you can reach someone when something is wrong.
Why both cause gut symptoms: the mechanism
This isn't a mystery or a manufacturing defect. It's the medication doing its job. Both drugs activate the GLP-1 receptor, and GLP-1 receptors sit in three places that matter here:
In the stomach. GLP-1 signaling slows gastric emptying - the rate at which your stomach passes food to the intestine. FDA labeling for semaglutide states this directly, and a 2025 review in Endocrinology found long-acting agents increase gastric half-emptying time by up to about 1.6-fold. Food stays put longer. That's the fullness you feel, and also the nausea, the reflux, and the "I ate four bites and I'm done" sensation.
In the brainstem. The area postrema and adjacent nuclei - the region that governs nausea and vomiting - are rich in GLP-1 receptors and sit outside the blood-brain barrier. Activating them produces satiety and, at sufficient intensity, queasiness. Same circuit.
Throughout the gut. Altered motility downstream explains why some people get diarrhea and others get constipation, sometimes the same person in the same month.
This changes how you interpret symptoms. Nausea in week two isn't a sign something's wrong — it's the medication working on the exact tissue it's designed to work on, at a dose your body hasn't adapted to yet. Persistent, severe, or escalating symptoms are a different matter, and I'll come to those.
What the trials reported, with a large caveat first
The most common mistake I see is lining up percentages from two different trials and declaring a winner. You can't do that. STEP 1 and SURMOUNT-1 enrolled different people, in different years, at different sites, with different definitions and reporting practices. Cross-trial comparison of adverse event rates is not valid evidence. I'm showing you both because you should see real numbers, not because the columns are comparable.
Semaglutide 2.4 mg - STEP 1 (NEJM, 2021; 1,961 adults; 68 weeks):
The investigators described GI events as typically transient and mild-to-moderate.
Tirzepatide - SURMOUNT-1 (NEJM, 2022; 2,539 adults; 72 weeks):
Look at the placebo columns, too. A meaningful fraction of people on nothing at all reported nausea, diarrhea, and constipation — a useful reminder that not every symptom appearing after you start a medication was caused by it. And discontinuation rates of 4–7% mean the large majority of participants stayed on treatment. Common does not mean intolerable.
The head-to-head data
Two trials have compared these molecules directly.
SURMOUNT-5 (NEJM, 2025) randomized 751 adults with obesity and without diabetes to maximum tolerated doses of tirzepatide or semaglutide for 72 weeks. Average weight reduction was −20.2% with tirzepatide versus −13.7% with semaglutide. Adverse events in both groups were predominantly gastrointestinal and mild-to-moderate, occurring mainly during dose escalation. Discontinuation due to adverse events was 6.1% with tirzepatide and 8.0% with semaglutide; GI events specifically leading to discontinuation were 2.7% versus 5.6%.
The critical caveat, stated by the investigators: the trial was not powered to compare safety between arms. It was built to compare weight outcomes. The tolerability figures are worth knowing and are not proof of a tolerability advantage.
SURPASS-2 (NEJM, 2021) compared tirzepatide against semaglutide 1 mg in 1,879 adults with type 2 diabetes over 40 weeks — a lower semaglutide dose than is used for weight management, so read it accordingly. Nausea occurred in 17.4%, 19.2%, and 22.1% at tirzepatide 5, 10, and 15 mg versus 17.9% with semaglutide 1 mg. Discontinuation due to adverse events was 5.1%, 7.7%, and 7.9% with tirzepatide versus 3.8% with semaglutide.
Notice that SURPASS-2 and SURMOUNT-5 point in somewhat different directions on tolerability. That's real, and it's why I won't tell you one of these medications is gentler than the other as a general rule. In my practice, I've had patients who couldn't tolerate one and did fine on the other — in both directions.
The side effects that aren't your gut
Less discussed, worth knowing, drawn from FDA labeling:
Semaglutide labeling reports single figures; tirzepatide labeling reports ranges, and I've kept them as ranges rather than collapsing them to a point. These come from separate labeling programs and are not a comparison.
- Fatigue: 11% for semaglutide; 5–7% for tirzepatide, in respective labeling.
- Hair shedding: 3% of adults on semaglutide 2.4 mg versus 1% on placebo; 4–5% for tirzepatide. Generally the body's response to rapid weight loss rather than a direct drug effect, and typically temporary.
- Heart rate: semaglutide labeling reports mean increases of 1–4 beats per minute.
- Injection site reactions: 1.4% versus 1% on placebo for semaglutide; 6–8% for tirzepatide.
- Headache, dizziness, burping, reflux, flatulence: all appear in the common-reactions lists.
- Hypoglycemia: low risk alone, because GLP-1's insulin effect is glucose-dependent. But semaglutide labeling reports clinically significant hypoglycemia in 6.2% of patients with type 2 diabetes versus 2.5% on placebo, and the risk rises meaningfully with concurrent insulin or sulfonylurea use.
Serious but uncommon: what both labels warn about
I'm not going to soften this section, and I'm not going to sensationalize it either. These are the warnings in FDA labeling for both medications.
Thyroid C-cell tumors (boxed warning). Both carry a boxed warning based on rodent studies. Semaglutide causes thyroid C-cell tumors in rodents at clinically relevant exposures; tirzepatide causes them in rats. Labeling for both states it is unknown whether these effects occur in humans. Both are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Acute pancreatitis. Reported with both. In semaglutide weight-management trials, it occurred in 4 treated patients (0.2 cases per 100 patient-years) versus 1 on placebo. In tirzepatide weight-reduction trials, labeling reports 0.2% in both the treated and placebo groups. Uncommon in absolute terms - and both labels direct that the medication be stopped if pancreatitis is suspected. Severe, persistent abdominal pain, often radiating to the back, is the symptom to know.
Gallbladder disease. Rapid weight loss raises gallstone risk generally, and GLP-1 signaling also slows gallbladder emptying. Semaglutide labeling reports cholelithiasis in 1.6% versus 0.7% on placebo, and cholecystitis in 0.6% versus 0.2%. Tirzepatide labeling reports cholelithiasis in 1.1% versus 1%, and cholecystitis in 0.7% versus 0.2%.
Acute kidney injury from volume depletion. Not a direct kidney toxicity - a downstream consequence of vomiting and diarrhea leading to dehydration. This is the one I watch most closely, because it's preventable and because patients underestimate it. If you can't keep fluids down, that's a phone call, not a wait-and-see.
Severe gastrointestinal reactions. Both labels note GI reactions that are sometimes severe, and neither is recommended in people with severe gastroparesis.
Diabetic retinopathy complications. In patients with type 2 diabetes, semaglutide labeling reports diabetic retinopathy in 4% versus 2.7% on placebo. Relevant if you have diabetes and existing retinopathy.
Pulmonary aspiration during anesthesia. There are postmarketing reports of aspiration in patients on GLP-1 medications undergoing general anesthesia or deep sedation, because food may remain in the stomach longer than expected. A 2024 multisociety guidance from the American Society of Anesthesiologists, the American Gastroenterological Association, and three other societies concluded that most patients can continue their GLP-1 medication before elective surgery with individualized assessment, with a 24-hour liquid-only diet for higher-risk patients and deferral of elective procedures during dose escalation or while GI symptoms are active. Tell every surgeon, anesthesiologist, and endoscopist that you're on this medication. Every time.
Hypersensitivity reactions. Listed for both; both are contraindicated in anyone with known serious hypersensitivity to the drug.
Who should not take these at all
From FDA labeling for both medications:
- Anyone with a personal or family history of medullary thyroid carcinoma
- Anyone with Multiple Endocrine Neoplasia syndrome type 2
- Anyone with known serious hypersensitivity to the drug or its components
- During pregnancy - semaglutide labeling states weight loss offers no benefit to a pregnant patient and may cause fetal harm, and directs discontinuation when pregnancy is recognized
Labeling also states neither is recommended in severe gastroparesis.
Beyond the absolute contraindications, other situations require clinical judgment rather than a yes or no: a history of pancreatitis, known gallbladder disease, type 1 diabetes, current insulin or sulfonylurea therapy, significant kidney disease, a history of an eating disorder, existing diabetic retinopathy, or plans to conceive. None is automatically disqualifying. All of them change the conversation — and someone has to know your history well enough to notice which applies to you.
Why slow titration is the main lever
FDA labeling for both drugs specifies escalation over months, and both state the reason plainly: to reduce the risk of gastrointestinal adverse reactions. Semaglutide starts at 0.25 mg weekly and steps up every four weeks - 0.5, 1, 1.7 - to a 2.4 mg maintenance dose. Tirzepatide starts at 2.5 mg weekly and steps up in 2.5 mg increments every four weeks, with maintenance at 5, 10, or 15 mg.
Symptoms cluster during escalation. In both SURMOUNT-1 and SURMOUNT-5, adverse events occurred predominantly during dose increases, and there's evidence the gastric emptying effect diminishes with continued treatment. That fits what patients report - week two of a new dose is usually worse than week four.
Which leads to the part patients most need to hear: the schedule is a floor, not a ceiling. If a step up is going badly, holding at the current dose longer is a legitimate clinical decision, not a failure. Rushing the titration is one of the most common ways this goes wrong.
When to call your doctor
Common, expected, and usually manageable: mild-to-moderate nausea, early fullness, constipation, loose stools, burping, and fatigue in the first weeks after a dose change. Reach out promptly for:
- Severe or persistent abdominal pain, especially radiating to the back - possible pancreatitis
- Right upper abdominal pain, fever, or yellowing of the skin or eyes - possible gallbladder disease
- Vomiting you can't stop, or an inability to keep fluids down - dehydration and kidney risk
- Signs of dehydration: dizziness on standing, markedly reduced urination, dark urine
- A neck lump, difficulty swallowing, persistent hoarseness, or shortness of breath
- Rash, swelling of the face or throat, or trouble breathing - possible hypersensitivity reaction
- Symptomatic low blood sugar, particularly if you take insulin or a sulfonylurea
- Any change in vision, particularly with diabetes
- Before any surgery or procedure with sedation - tell the team you're on this medication
This is where the structure of your care matters as much as the molecule. My patients can message me. I tell them they're never bothering me, and I mean it - a question at week three is often what keeps a small problem small. I spent fifteen years in emergency medicine watching what happens when people don't have anyone to ask.
A note on compounded medications
Some practices, including mine, work with compounded formulations of semaglutide and tirzepatide, and it belongs in a side effects article for a specific reason.
Compounded medications are not FDA-approved finished drug products, and FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed. FDA has published concerns specific to this market, including adverse event reports linked to dosing errors - patients drawing up the wrong amount, or being prescribed doses, frequencies, or escalation schedules beyond what approved labeling supports - along with reports of products shipped without adequate cooling and of counterfeit products.
That's not a reason to panic. It's a reason to be precise about who is prescribing, what dose, in what units, and whether you can reach them.
Frequently asked questions
Which has fewer side effects, semaglutide or tirzepatide?
There isn't a clean answer. In SURMOUNT-5, discontinuation due to GI events was lower with tirzepatide (2.7%) than semaglutide (5.6%), but that trial was not powered to compare safety. In SURPASS-2, discontinuation due to adverse events was lower with semaglutide 1 mg than with tirzepatide - though that used a lower semaglutide dose. Individual tolerance varies substantially and can't be predicted from trial averages.
Do the side effects go away?
For most people in the trials, GI events were transient and mild-to-moderate, concentrated around dose increases. That doesn't hold for everyone, and results vary. Persistent or severe symptoms warrant a conversation about dose, not endurance.
Can I switch from one to the other if I can't tolerate it?
Sometimes appropriate, sometimes not - it depends on why you're not tolerating the first one, your medical history, and what dose you're at. That's a clinical decision, not one to make from a forum thread.
Does the thyroid boxed warning mean these cause cancer?
The warning is based on thyroid C-cell tumors observed in rodents at clinically relevant exposures. FDA labeling for both medications states it is unknown whether this occurs in humans. What follows practically is the contraindication: if you or a close relative has had medullary thyroid carcinoma or MEN 2, these medications are not for you.
How do I reduce nausea?
Titrating slowly under physician supervision is the lever with labeling behind it - both labels state escalation exists to reduce GI reactions. Beyond that, general measures are worth discussing with your clinician in the context of your own situation rather than applied from a list.
Should I stop before surgery?
The 2024 multisociety guidance concluded most patients can continue before elective surgery with individualized assessment. What isn't optional is telling your surgical and anesthesia team you're taking it, so they can make that call.
If you're trying to decide
That's exactly what an initial visit is for.
I can't tell you from a page on the internet which of these medications belongs in your care, or whether either does. What I can tell you is that the decision turns on your history, your labs, your other medications, and your tolerance — and that it should be made by a physician who will still be reachable when you're three weeks in with a question at nine at night.
For more on the underlying biology, read our companion piece on how semaglutide and tirzepatide work.
Billie Jean Health is a physician-led telehealth practice serving patients in Texas. If you have questions, ask them.
Ozempic® and Wegovy® are registered trademarks of Novo Nordisk. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Billie Jean Health is not affiliated with, endorsed by, or sponsored by either company.
This article is for general education and is not medical advice for any individual. It doesn't establish a physician-patient relationship. Talk to a licensed clinician about your own situation.